{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T02:25:34Z","timestamp":1762050334690,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T00:00:00Z","timestamp":1688774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T00:00:00Z","timestamp":1688774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s10147-023-02381-3","type":"journal-article","created":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T13:02:02Z","timestamp":1688821322000},"page":"1139-1146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Site of distant metastasis affects the prognosis with recurrent\/metastatic head and neck squamous cell carcinoma patients treated with Nivolumab"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5652-6665","authenticated-orcid":false,"given":"Yuta","family":"Hoshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Shirakura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Koide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Tamii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyohei","family":"Kamata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Yokomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sotaro","family":"Osaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Yagihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Beppu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,8]]},"reference":[{"issue":"8","key":"2381_CR1","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/S0959-8049(00)00054-X","volume":"36","author":"LP Kowalski","year":"2000","unstructured":"Kowalski LP, Carvalho AL (2000) Natural history of untreated head and neck cancer. Eur J Cancer 36(8):1032\u20131037","journal-title":"Eur J Cancer"},{"issue":"19","key":"2381_CR2","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856\u20131867","journal-title":"N Engl J Med"},{"issue":"12","key":"2381_CR3","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3390\/cancers10120466","volume":"10","author":"D Nishikawa","year":"2018","unstructured":"Nishikawa D, Suzuki H, Koide Y et al (2018) Prognostic markers in head and neck cancer patients treated with Nivolumab. Cancers (Basel) 10(12):466","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2381_CR4","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1007\/s00405-020-05945-5","volume":"277","author":"Y Ueki","year":"2020","unstructured":"Ueki Y, Takahashi T, Ota H et al (2020) Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score. Eur Arch Otorhinolaryngol 277(8):2341\u20132347","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"2","key":"2381_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/00016489.2019.1699250","volume":"140","author":"T Ueda","year":"2020","unstructured":"Ueda T, Chikuie N, Takumida M et al (2020) Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with clinical outcome in recurrent or metastatic head and neck cancer patients treated with nivolumab. Acta Otolaryngol 140(2):181\u2013187","journal-title":"Acta Otolaryngol"},{"issue":"1","key":"2381_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10147-021-02047-y","volume":"27","author":"R Yasumatsu","year":"2022","unstructured":"Yasumatsu R, Shimizu Y, Hanai N et al (2022) Outcomes of long-term nivolumab and subsequent chemotherapy in Japanese patients with head and neck cancer: 2-year follow-up from a multicenter real-world study. Int J Clin Oncol 27(1):95\u2013104","journal-title":"Int J Clin Oncol"},{"issue":"9","key":"2381_CR7","doi-asserted-by":"publisher","first-page":"5277","DOI":"10.21873\/anticanres.14532","volume":"40","author":"C Fushimi","year":"2020","unstructured":"Fushimi C, Okamoto I, Matsuki T et al (2020) Salvage chemotherapy after nivolumab for recurrent or metastatic head and neck carcinoma. Anticancer Res 40(9):5277\u20135283","journal-title":"Anticancer Res"},{"issue":"2","key":"2381_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/coa.13668","volume":"46","author":"I Lardinois","year":"2021","unstructured":"Lardinois I, Dequanter D, Lechien JR et al (2021) Survival and treatment outcome of head and neck cancer patients with pulmonary oligometastases. Clin Otolaryngol 46(2):311\u2013317","journal-title":"Clin Otolaryngol"},{"issue":"6","key":"2381_CR9","doi-asserted-by":"publisher","first-page":"E1838","DOI":"10.1002\/lary.29208","volume":"131","author":"CA Bollig","year":"2021","unstructured":"Bollig CA, Newberry CI, Galloway TLI et al (2021) Prognostic impact of metastatic site and pattern in patients with metastatic head and neck cancer. Laryngoscope 131(6):E1838\u2013E1846","journal-title":"Laryngoscope"},{"issue":"5","key":"2381_CR10","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.oraloncology.2005.01.012","volume":"41","author":"LP Kowalski","year":"2005","unstructured":"Kowalski LP, Carvalho AL, Martins Priante AV et al (2005) Predictive factors for distant metastasis from oral and oropharyngeal squamous cell carcinoma. Oral Oncol 41(5):534\u2013541","journal-title":"Oral Oncol"},{"issue":"10","key":"2381_CR11","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1007\/s10147-021-01965-1","volume":"26","author":"A Nishimura","year":"2021","unstructured":"Nishimura A, Yokota T, Hamauchi S et al (2021) Incurable locoregional disease is a strong poor prognostic factor in recurrent or metastatic squamous cell carcinoma of the head and neck. Int J Clin Oncol 26(10):1822\u20131830","journal-title":"Int J Clin Oncol"},{"key":"2381_CR12","doi-asserted-by":"publisher","first-page":"651086","DOI":"10.3389\/fimmu.2021.651086","volume":"12","author":"XJ Chen","year":"2021","unstructured":"Chen XJ, Ren A, Zheng L et al (2021) Pan-cancer analysis identifies liver metastases as negative predictive factor for immune checkpoint inhibitors treatment outcome. Front Immunol 12:651086","journal-title":"Front Immunol"},{"issue":"1","key":"2381_CR13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12916-022-02315-2","volume":"20","author":"SC Ma","year":"2022","unstructured":"Ma SC, Bai X, Guo XJ et al (2022) Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice. BMC Med. 20(1):120","journal-title":"BMC Med."},{"issue":"3","key":"2381_CR14","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48(3):452\u2013458","journal-title":"Bone Marrow Transplant"},{"key":"2381_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ejca.2022.07.034","volume":"175","author":"LS Ter Maat","year":"2022","unstructured":"Ter Maat LS, van Duin IAJ, Elias SG et al (2022) Imaging to predict checkpoint inhibitor outcomes in cancer. A systematic review. Eur J Cancer 175:60\u201376","journal-title":"Eur J Cancer"},{"issue":"10","key":"2381_CR16","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","volume":"5","author":"SL Topalian","year":"2019","unstructured":"Topalian SL, Hodi FS, Brahmer JR et al (2019) Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with Nivolumab. JAMA Oncol 5(10):1411\u20131420","journal-title":"JAMA Oncol"},{"issue":"16","key":"2381_CR17","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.1158\/1078-0432.CCR-22-0630","volume":"28","author":"H Yukami","year":"2022","unstructured":"Yukami H, Kawazoe A, Lin YT et al (2022) Updated efficacy outcomes of anti-PD-1 antibodies plus multikinase inhibitors for patients with advanced gastric cancer with or without liver metastases in clinical trials. Clin Cancer Res 28(16):3480\u20133488","journal-title":"Clin Cancer Res"},{"key":"2381_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2021.100831","volume":"37","author":"KM Miller","year":"2021","unstructured":"Miller KM, Filippova OT, Hayes SA et al (2021) Pattern of disease and response to pembrolizumab in recurrent cervical cancer. Gynecol Oncol Rep 37:100831","journal-title":"Gynecol Oncol Rep"},{"issue":"1","key":"2381_CR19","doi-asserted-by":"publisher","first-page":"14319","DOI":"10.1038\/s41598-022-18611-z","volume":"12","author":"T Matoba","year":"2022","unstructured":"Matoba T, Minohara K, Kawakita D et al (2022) Impact of tumor burden on survival in patients with recurrent or metastatic head and neck cancer treated with immune checkpoint inhibitors. Sci Rep 12(1):14319","journal-title":"Sci Rep"},{"issue":"1","key":"2381_CR20","doi-asserted-by":"publisher","first-page":"16992","DOI":"10.1038\/s41598-021-96538-7","volume":"11","author":"K Minohara","year":"2021","unstructured":"Minohara K, Matoba T, Kawakita D et al (2021) Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab. Sci Rep 11(1):16992","journal-title":"Sci Rep"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02381-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-023-02381-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02381-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T01:02:44Z","timestamp":1693443764000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-023-02381-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,8]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["2381"],"URL":"https:\/\/doi.org\/10.1007\/s10147-023-02381-3","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2023,7,8]]},"assertion":[{"value":"24 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No author has any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}